Sigma-Aldrich Introduces MISSION(R) esiRNA for Low Cost, High Specificity Pooled RNAi Screening
ST. LOUIS, April 28 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL ) today announced the global release of MISSION(R) esiRNA, a pool of gene-specific siRNA that provides a novel and powerful approach to
RNAi screening in mammalian cells. Unlike traditional synthetic RNAi, esiRNA ( htt...
Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC
(OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the
development of technologies that target the science of healthy aging, today
announced an agreement with the Institute of Bioorganic Chemistry of the
Polish Academy of Sci...
Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
PALO ALTO, Calif., Dec. 2 /PRNewswire/ -- Intradigm Corporation, a leading
developer of targeted, systemic RNA interference (RNAi) therapeutics, today
announced the issuance of United States patent 7,459,547, entitled "Methods
and Compositions for Controlling Efficacy of RNA Silencing." The issue...
Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL )
announced today the global release of MISSION(R) In VIVO QUALITY and iScale
Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA are
expected to allow researchers to successfully take the next step in ...
Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System
GOTHENBURG, Sweden, November 12 /PRNewswire/ -- Cellectricon, a leading
provider of advanced screening solutions for drug discovery, has today
received its most significant and largest single order to date. The order
includes three Cellaxess(R)HT systems and the customer is a leading US
biotec...
Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
Researchers gain access to Sigma-Aldrich's leading MISSION(TM) shRNA libraries
ST. LOUIS, Oct. 15 /PRNewswire/ -- Sigma-Aldrich (Nasdaq: SIAL ), a
leading life science company and member of The
RNAi Consortium (TRC),
proudly welcomes the Memorial Sloan-Ketterin...
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
FREMONT, Calif., Sept. 17 /PRNewswire/ -- Quark Pharmaceuticals, Inc.,
a development-stage pharmaceutical company discovering and developing novel
RNA interference (RNAi)-based therapeutics, today announced the
presentation of posters at the 5th Annual
RNAi Europe, taking place
September 16-18...
Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
U.S. AtuRNAi Patent Allowance Builds on European Equivalent Granted in 2007, Expanding Commercial Protection
LONDON, July 31 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a
leading European
RNAi focused biotechnology company, today announced that
the United States Paten...
Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
Sigma-Aldrich to Provide Full Functional Validation Data for Its MISSION(R) shRNA Collection
ST. LOUIS, May 7 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq:
SIAL) and the second phase of The
RNAi Consortium (TRC2) have commenced
functional validation of the Conso...
febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
RNA, microRNA Researchers Comprise One of the Main User Groups of febit's Simplified and Automated Microarray Technology
MEDFORD, Mass., and HEIDELBERG, Germany, April 22 /PRNewswire/ -- febit
holding gmbh today announced it will introduce the Geniom RT Analyzer(R) to
the U.S. marke...
Open Biosystems' Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
Unique program continues to advance collaborative research worldwide
HUNTSVILLE, Ala., April 7, 2008 /PRNewswire/ -- Open Biosystems, Inc.,
announced today that leading research institutions, the Institute for
Molecular Bioscience and Diamantina Institute at the University of
Queensland, and...
Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
TOKYO and SAN JOSE, Calif., March 12 /PRNewswire/ -- Oncolys BioPharma,
Inc. (Tokyo, Japan) and Tacere Therapeutics, Inc. (San Jose, CA, USA)
announced today that they have entered into a strategic alliance and
license agreement to develop and commercialize throughout Asia, Tacere's
RNA interf...
Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
ROCKVILLE, Md., March 12 /PRNewswire/ -- General Research Laboratory,
Inc. (GRL) and Sirnaomics, Inc. announced today that the companies are
advancing their partnership initiated in July 2007 for development of two
RNA interference (RNAi) therapeutic products, following the successful
identifi...
Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
LAS VEGAS, March 11 /PRNewswire/ -- Altogen Biosystems
( http://www.altogen.com ) announced launch of new contract research
services. Located in Las Vegas, NV, Altogen Custom Services focus on
providing specialized biotechnology and pharmaceutical services, including
RNA Interference (RNAi) se...
Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
Genome scale
RNAi analysis affordable and accessible to all researchers
HUNTSVILLE, Ala., March 11 /PRNewswire/ -- Open Biosystems, Inc.
announced today that Harvard Medical School and the University of North
Carolina have joined the Open Access(TM)
RNAi Program. Each University
purchased acce...
Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect
Mike Byrom, Vince
Pallotta, David Brown*, and Lance Ford* Ambion, Inc.
2130 Woodward Street Austin, TX 78744-1832 * Corresponding authors
dbrown@ambion.com , Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
...ng drug candidates using Cequent's proprietary tk
rnai delivery platform against a series of targets thou... drug candidate CEQ508, an orally administered tk
rnai therapeutic targeting the primary oncogene (beta-c...acy. This is a testament to the promise of our tk
rnai technology -- but also to Stephen's skills and ten...
Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
...fication tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification;
rnai and stem cell studies; and plant and food research. For more information visit www.clontech.com .
About Takara Bio Inc.
Takara Bio Inc. i...
GeneCards(R) Version 3.0 Beta Released
...drugs & compounds and direct links to valuable research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and
rnai reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel, direct...
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
...m that spans therapeutic target identification to drug development. Quark's
rnai technology includes novel siRNA structures and chemistry providing Quark wi...rnally. The Company expects to utilize the structures to develop additional
rnai drug candidates.
Quark is headquartered in Fremont, California and ope...
Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn
...ulting in a larger, healthier root system for a plant. The Phase II grant will allow Divergence to expand greenhouse testing in crops including corn.
rnai is a fundamental mechanism of gene regulation triggered by double-stranded RNA. Divergence was an early industrial adopter of RNAi, working with the ...
Roche Madison Moves to New Facility
...c acid based technologies, including a proprietary
rnai (Ribonucleic Acid interference) delivery platform.
rnai - a natural mechanism that the body uses to 'silen...andscape and to finding innovative ways of getting
rnai therapeutics into specific disease targets to bene...
Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
... of oligonucleotide therapeutics. Other leaders in
rnai will also present during the session including: Pa...Special issues in the discovery and development of
rnai therapeutics); Christina Gamba-Vitalo, Senior Dire...ion in this session alongside respected leaders in
rnai development. The invitation reinforces that the dr...
Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization of Protein Biomarkers Associated With Neurological Conditions
...s & compounds and direct links to cutting-edge research reagents and tools such as antibodies, recombinant proteins, clones, expression assays and
rnai reagents. GeneCards was developed over the last 12 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel.
...
Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
...assays market, the research ELISA market, the high content screening market, the liquid chromatography market, the protein electrophoresis market, the
rnai market, and the proteomics array market."
Life Technologies offers approximately 50,000 products and lays claim to an incredibly strong technolog...
Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
...eriments could be performed, stem cell differentiation can be observed, and
rnai knockdowns could be performed.
"The cellTRAY(R) Imaging System can be ...m cell research, toxicology research, Nano particle, C dot, Q dot research,
rnai research and IVF research," notes Priya. "Further, the company has four iss...
Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
...any Patents in Each of the Three Critical Areas of
rnai Therapeutic Development
PALO ALTO, Calif., Ma...(IP) covering each of the three critical areas for
rnai therapeutic development: target sequences, deliver...Intradigm in a uniquely strong position within the
rnai therapeutic industry, especially among other priva...
Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
...ortal's expanding line of cutting-edge technologies for stem cell research includes the industry's most highly-validated shRNA library, the MISSION(R)
rnai portfolio, which enables gene silencing across a wide range of cellular targets. The site also features the CompoZrTM zinc finger nuclease (ZFN) reage...
Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
...m/lentiplex ). Using the shRNA collections of The
rnai Consortium (TRC), the MISSION LentiPlex Pooled shRNA Libraries enable rapid, genome-wide
rnai screening at the bench-top level in a convenient a... format enables researchers to perform genome-wide
rnai screens on various cell types, rapidly and efficie...
Cequent Names Ted Hibben Chief Business Officer
...even more important as we continue to move our tk
rnai technology from the laboratory into clinical devel...e to license our technology to deliver therapeutic
rnai for novel metabolic, oncology, or other targets." ...genic bacteria as an engine to produce and deliver
rnai directly into cells. It is based on ground-breakin...